109 related articles for article (PubMed ID: 25862876)
1. Epirubicin plus paclitaxel regimen as second-line treatment of patients with small-cell lung cancer.
Pasello G; Carli P; Canova F; Bonanno L; Polo V; Zago G; Urso L; Conte P; Favaretto A
Anticancer Res; 2015 Apr; 35(4):2183-9. PubMed ID: 25862876
[TBL] [Abstract][Full Text] [Related]
2. Phase II multicentre study of efficacy and feasibility of dose-intensified preoperative weekly cisplatin, epirubicin, and paclitaxel (PET) in resectable gastroesophageal cancer.
Jary M; Ghiringhelli F; Jacquin M; Fein F; Nguyen T; Cleau D; Nerich V; El Gani M; Mathieu P; Valmary-Degano S; Arnould L; Lassabe C; Lamfichekh N; Fratté S; Paget-Bailly S; Bonnetain F; Borg C; Kim S
Cancer Chemother Pharmacol; 2014 Jul; 74(1):141-50. PubMed ID: 24824852
[TBL] [Abstract][Full Text] [Related]
3. Second-line chemotherapy in recurrent small cell lung cancer. Results from a crossover schedule after primary treatment with cisplatin and etoposide (EP-regimen) or cyclophosphamide, epirubicin, and vincristin (CEV-regimen).
Sundstrøm S; Bremnes RM; Kaasa S; Aasebø U; Aamdal S;
Lung Cancer; 2005 May; 48(2):251-61. PubMed ID: 15829326
[TBL] [Abstract][Full Text] [Related]
4. Phase I studies of combined paclitaxel/epirubicin and paclitaxel/epirubicin/cyclophosphamide in patients with metastatic offast cancer: the French experience.
Catimel G; Spielmann M; Dieras V; Tubiana-Hulin M; Bonneterre J; Pouillart P; Kayitalire L; Guastalla JP; Graffand N; Garet F; Dumortier A; Pellae-Cosset B
Semin Oncol; 1997 Feb; 24(1 Suppl 3):S8-12. PubMed ID: 9071333
[TBL] [Abstract][Full Text] [Related]
5. Accelerated cisplatin and high-dose epirubicin with G-CSF support in patients with relapsed non-small-cell lung cancer: feasibility and efficacy.
Huisman C; Biesma B; Postmus PE; Giaccone G; Schramel FM; Smit EF
Br J Cancer; 2001 Nov; 85(10):1456-61. PubMed ID: 11720428
[TBL] [Abstract][Full Text] [Related]
6. Weekly dose-dense cisplatin-epirubicin-paclitaxel administration with granulocyte colony-stimulating factor support does not substantially improve prognosis in extensive disease small-cell lung cancer. A SICOG phase II study.
Frasci G; Comella P; Carreca I; DeCataldis G; Muci D; Brunetti C; Russo A; Palmeri S; D'Aniello R; Giordano R; D'Aiuto M; Comella G;
Oncology; 2005; 68(2-3):223-9. PubMed ID: 16015038
[TBL] [Abstract][Full Text] [Related]
7. Phase 2 study of NAB-paclitaxel in SensiTivE and refractory relapsed small cell lung cancer (SCLC) (NABSTER TRIAL).
Gelsomino F; Tiseo M; Barbieri F; Riccardi F; Cavanna L; Frassoldati A; Delmonte A; Longo L; Dazzi C; Cinieri S; Colantonio I; Sperandi F; Lamberti G; Brocchi S; Tofani L; Boni L; Ardizzoni A
Br J Cancer; 2020 Jul; 123(1):26-32. PubMed ID: 32346071
[TBL] [Abstract][Full Text] [Related]
8. Epirubicin and ifosfamide in relapsed or refractory small cell lung cancer patients.
Jacot W; Pujol JL; Chakra M; Molinier O; Bozonnat MC; Gervais R; Quantin X
Lung Cancer; 2012 Feb; 75(2):213-6. PubMed ID: 21831476
[TBL] [Abstract][Full Text] [Related]
9. Real-life second-line epirubicin-paclitaxel regimen as treatment of relapsed small-cell lung cancer: EpiTax study.
Annic J; Babey H; Corre R; Descourt R; Quéré G; Renaud E; Lambert M; Le Noac'h P; Dhamelincourt E; Nguyen J; Vu A; Bourbonne V; Robinet G; Geier M
Cancer Med; 2023 Feb; 12(3):2658-2665. PubMed ID: 36000584
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of metronomic administration of paclitaxel for advanced recurrent non-small-cell lung cancer.
Noronha V; Patil VM; Joshi A; Prabhash K
Indian J Cancer; 2013; 50(2):122-7. PubMed ID: 23979203
[TBL] [Abstract][Full Text] [Related]
11. Activity and safety of epirubicin plus paclitaxel in advanced breast cancer.
Conte PF; Michelotti A; Baldini E; Tibaldi C; DaPrato M; Salvadori B; Giannessi PG; Gentile A; Biadi O; Mariani M
Semin Oncol; 1996 Feb; 23(1 Suppl 1):28-32. PubMed ID: 8629033
[TBL] [Abstract][Full Text] [Related]
12. Paclitaxel, epirubicin, and cisplatin (TEP) regimen as neoadjuvant treatment in locally advanced cervical cancer: long-term results.
Ferrandina G; Distefano MG; De Vincenzo R; Salutari V; Petrillo M; Scarciglia ML; Pietragalla A; Conte C; Scambia G
Gynecol Oncol; 2013 Mar; 128(3):518-23. PubMed ID: 23237767
[TBL] [Abstract][Full Text] [Related]
13. A dose-finding study of epirubicin in combination with paclitaxel in the treatment of advanced breast cancer.
Conte PF; Michelotti A; Baldini E; Salvadori B; Gennari A; Da Prato M; Tibaldi C; Salzano E; Gentile A
Semin Oncol; 1996 Oct; 23(5 Suppl 11):28-31. PubMed ID: 8893896
[TBL] [Abstract][Full Text] [Related]
14. [Safety of adjuvant dose-dense chemotherapy with paclitaxel and epirubicin for high-risk breast cancer].
Wu WH; Li Q; Xu BH; Zhang P; Zhao LM; Yuan P; Wang JY; Cai RG; Zhou AP
Zhonghua Zhong Liu Za Zhi; 2008 Jul; 30(7):548-51. PubMed ID: 19062727
[TBL] [Abstract][Full Text] [Related]
15. Paclitaxel plus bevacizumab in patients with chemoresistant relapsed small cell lung cancer as salvage treatment: a phase II multicenter study of the Hellenic Oncology Research Group.
Mountzios G; Emmanouilidis C; Vardakis N; Kontopodis E; Hatzidaki D; Popis E; Karachaliou N; Kotsakis A; Agelidou M; Georgoulias V
Lung Cancer; 2012 Jul; 77(1):146-50. PubMed ID: 22418242
[TBL] [Abstract][Full Text] [Related]
16. Methotrexate-paclitaxel-epirubicin-carboplatin (M-TEC) combination chemotherapy in patients with advanced bladder cancer: an open label phase II study.
Tsavaris N; Kosmas C; Skopelitis H; Dimitrakopoulos A; Kopterides P; Bougas D; Stravodimos K; Mitropoulos D; Alamanis C; Giannopoulos A
J Chemother; 2005 Aug; 17(4):441-8. PubMed ID: 16167525
[TBL] [Abstract][Full Text] [Related]
17. Survival outcome of inoperable non-small cell lung cancer patients receiving conventional dose epirubicin and Paclitaxel as first-line treatment.
Yang CH; Chen MC; Cheng AL; Hsu CH; Yeh KH; Yu YC; Whang-Peng J; Yang PC
Oncology; 2005; 68(4-6):350-5. PubMed ID: 16020962
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant treatment of locally advanced carcinoma of the uterine cervix with epirubicin, paclitaxel and cisplatin.
D'Agostino G; Distefano M; Greggi S; Salerno M; Ferrandina G; Poerio A; Mancuso S; Scambia G
Cancer Chemother Pharmacol; 2002 Mar; 49(3):256-60. PubMed ID: 11935219
[TBL] [Abstract][Full Text] [Related]
19. A phase II study of weekly paclitaxel and epirubicin in recurrent or refractory squamous cell carcinoma of the head and neck.
Wang TF; Chu SC; Kao RH; Yao CY; Li CC
Jpn J Clin Oncol; 2008 Jul; 38(7):459-63. PubMed ID: 18586668
[TBL] [Abstract][Full Text] [Related]
20. Phase I study of paclitaxel and epirubicin in patients with metastatic breast cancer: a preliminary report on safety.
Catimel G; Spielmann M; Dieras V; Kayitalire L; Pouillart P; Guastalla JP; Soler-Michel P; Graffand N; Garet F; Dumortier A; Pellae-Cosset B; Chazard M
Semin Oncol; 1996 Feb; 23(1 Suppl 1):24-7. PubMed ID: 8629032
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]